Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Editas Medicine

Intellia Therapeutics

CRISPR technology, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows scientists to make precise modifications to the DNA of living organisms. It's one of the hottest trends in the stock market today, so I've made a list of three of the most profitable CRISPR stocks to consider.

3 Profitable CRISPR Stocks Earning Analysts' Praise

Archer Aviation

Bandwidth

EHang Holdings Ltd - ADR

Ouster, Inc

StoneCo

Upstart Holdings

Growth stocks have been driving the market for most of its history, but the trends have only accelerated recently. Investors are willing to slap a higher and higher premium on these growth stocks as long as they can beat earnings and keep their growth figures high.

7 Growth Stocks to Invest $500 In and Cash Out $100K by 2030

Beam Therapeutics

Artificial intelligence stocks will be the choice of growth-oriented investors for years to come. But if you're a buy-and-hold investor with above-average patience, this is a time to look for undervalued gene editing stocks.

The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024

CRISPR Therapeutics AG investors have endured a challenging bear market decline. CRSP's buying momentum has waned as it struggles to stay above the $50 support level. Crispr's pipeline is mainly in the early stages, with Casgevy being the only commercially approved program.

Crispr Therapeutics: Beaten Down But Not Broken

Imagine this: you walk into a hospital for a procedure. You expect a long, traditional surgery with a lengthy recovery.

Forget Intuitive Surgical: This Stock Is the Next Millionaire Maker

Schrodinger 

Vertex Pharmaceuticals

Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9.

3 Top-Rated Gene Editing Stocks Actually Making Money

With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the best gene editing stocks to buy. That's because unlike more standard therapeutics such as antibiotics, antivirals and vaccines gene editing is a permanent solution most of the time.

You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.

Ginkgo Bioworks Holdings

Cassava Sciences Inc

In 2024, the iShares Biotechnology ETF (NASDAQ: IBB ) is up just over 1.5%. If you're looking for steady, dividend-paying stocks, you can find a number of biotech stocks to buy from the holdings in this fund.

Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich

Eli Lilly

Novavax

Biotech stocks to buy now reflect a more dynamic shift in investor focus of late.Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Global vaccine sales for the crippling virus were upwards of $142 billion from 2020 to 2023.

You've Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.

CRISPR Therapeutics is a gene-editing pioneer. Despite its landmark regulatory approvals with Casgevy, its shares have failed to excite the investment community.

Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued.

Regeneron Pharmaceuticals

In the world of investing, biotech stocks represent a unique blend of high risk and high reward. After a period of volatility in the broader markets in 2022 and 2023, biotech stocks are now drawing attention for their potential to deliver substantial long-term returns.

3 Biotech Stocks That Could Make Your Grandchildren Rich

Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body.

Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich

CRISPR Therapeutics AG (CRSP) closed at $56.63 in the latest trading session, marking a +1.22% move from the prior day.

CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing

Gene-editing stocks has been gaining substantial attention, as the industry holds the potential to revolutionize medicine. From curing genetic disorders to enhancing agricultural productivity, the applications are vast and transformative.

3 Gene Editing Stocks That Could Make Your Grandchildren Rich

IonQ

Joby Aviation

Chasing the next trend thing after AI is easier said than done. It is also a pretty risky strategy.

The Next Big Thing After AI? 3 Sleeper Stocks to Buy Before the Boom

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Most-Watched Stock CRISPR Therapeutics AG (CRSP) Worth Betting on Now?

CEVA

Chevron

LTC Properties

PepsiCo

Pixelworks

PayPal

Because it's tied to one of the six leading causes of “finality,” stress represents a silent public health crisis. And few things cause heightened stress than dealing with you-know-what at work.

7 ‘FIRE' Stocks to Put You on the Path to Financial Freedom

CRISPR Therapeutics AG (NASDAQ:CRSP ) Company Conference Call June 11, 2024 9:20 AM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon everyone, thank you for joining us. Really pleased to have Sam Kulkarni, CEO of CRISPR Therapeutics here with us.

CRISPR Therapeutics (CRSP) Presents at Goldman Sachs 45th Annual Global Healthcare Conference - Company Call Transcript

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Crispr Therapeutics' new gene-editing protocol gives it a legitimate claim to be the future of medicine. That powered the stock back in 2020-21. But at some point, it'll take revenues and profits, not futurism to justify stock ownership.

Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)

Cathie Wood loves bargains on potential long-term winners -- especially when the company is an innovator. One of her favorite technologies in healthcare is gene editing, and she's been loading up on two stocks in particular.

Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought

Alnylam Pharmaceuticals

Clover Health Investments

Enovix Corporation

General American Investors

Halliburton

Logistic Properties Of The Americas

Adams Natural Resources Fund Inc

POET Technologies Inc

Roivant Sciences Ltd

Uranium Royalty Corp

Voyager Therapeutics

The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, and Haliburton. Many of the ideas included have not been discussed in months on the site. One of the ideas is actually first-ever coverage for this ticker.

The 'Undercovered' Dozen From June 1-6

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?

Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?

CRISPR Therapeutics AG (NASDAQ:CRSP ) Jefferies 2024 Global Healthcare Conference June 5, 2024 10:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Maury Raycroft - Jefferies Maury Raycroft Good morning. My name is Maury Raycroft and I'm one of the biotech analysts at Jefferies.

CRISPR Therapeutics AG (CRSP) Jefferies 2024 Global Healthcare Conference (Transcript)

Buying the dip in a promising stock can be an effective strategy. CRISPR Therapeutics has a long way to go before becoming profitable.

Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?

News for CRISPR Therapeutics Stock (CRSP)